CTMX

$5.45

Pre-MarketAs of Mar 17, 8:00 PM UTC

CytomX Therapeutics, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$5.45
Potential Downside
39.7%
Whystock Fair Value$3.29
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology bio...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$923.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.17
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-35.25%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.98

Recent News

Zacks
Mar 17, 2026

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 16, 2026

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MT Newswires
Mar 16, 2026

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 16, 2026

CytomX Therapeutics Inc (CTMX) Q4 2025 Earnings Call Highlights: Promising Phase 1 Data and ...

CytomX Therapeutics Inc (CTMX) reports encouraging results from its Varseta-M study, with plans for a pivotal trial and expansion into new tumor types.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Mar 16, 2026

BC-Most Active Stocks

YY Group Holdings Ltd. 26,117,734 0.0511

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.